格隆汇9月26日丨和铂医药-B(02142.HK)公告，9月26日耗资70.4万港元回购5万股。 ...

和铂医药-B(02142)发布公告，于2025年9月26日斥资70.4万港元回购5万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 第 1 頁 共 7 頁 v 1.3.0 FF305 | 於下列日期結束時的結存 (註5及6) | | 2025年9月26日 | 871,930,522 | | 21,187,000 | | | 893,117,522 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | | | | | 購回股份（擬註銷但尚未註銷） | 1). | | 250,000 | 0.0327 % | | HKD | 2.25 | | | 變動日期 | 2025年1月8日 | | | | | | | | | 購回股份（擬註銷但尚未註銷） | 2). | | 156,000 | 0.0204 % | | HKD | 2.39468 | | | 2025年1月10日 | 變動日期 | | | | | | ...

中 報 2025 | 目錄 | | --- | | | | 4 財務摘要 5 業務摘要 9 管理層討論及分析 28 企業管治╱其他資料 43 中期簡明綜合損益表 44 中期簡明綜合全面收益表 45 中期簡明綜合財務狀況表 47 中期簡明綜合權益變動表 48 中期簡明綜合現金流量表 50 中期簡明綜合財務資料附註 76 釋義 和鉑醫藥控股有限公司 中期報告2025 2 公司資料 董事會 執行董事 王勁松博士 （首席執行官）（主席） 戎一平博士 獨立非執行董事 陳維維女士 Robert Irwin Kamen博士 葉小平博士 Albert R. Collinson博士 審核委員會 陳維維女士 （主席） 葉小平博士 Albert R. Collinson博士 薪酬委員會 Albert R. Collinson博士 （主席） 葉小平博士 王勁松博士 提名委員會 王勁松博士 （主席） Robert Irwin Kamen博士 葉小平博士 陳維維女士 授權代表 王勁松博士 戎一平博士 聯席公司秘書 呂穎一先生 劉毅博士 （自二零二五年六月九日起獲委任） 高一帆女士 （自二零二五年五月二十六日起辭任） 開曼群島註冊辦事處 ...

Summary of Key Points Core Viewpoint - Multiple companies, including Tencent Holdings and Anta Sports, conducted share buybacks on September 25, 2025, with Tencent leading in both the number of shares repurchased and the total amount spent [1]. Company Buyback Details - Tencent Holdings (00700) repurchased 844,000 shares for a total of 550 million, with a year-to-date total of 63.29 million shares, representing 0.689% of its total share capital [2]. - Anta Sports (02020) repurchased 1.065 million shares for 99.82 million, with a year-to-date total of 7.31 million shares, accounting for 0.260% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 8.1 million shares for 32.97 million, with a year-to-date total of 92.44 million shares, representing 0.080% of its total share capital [2]. - China Hongqiao Group (01378) repurchased 1 million shares for 24.87 million, with a year-to-date total of 153 million shares, accounting for 1.630% of its total share capital [2]. - CIMC (02039) repurchased 3.04 million shares for 23.37 million, with a year-to-date total of 24.78 million shares, representing 0.800% of its total share capital [2]. - Hang Seng Bank (00011) repurchased 200,000 shares for 23.13 million, with a year-to-date total of 7.93 million shares, accounting for 0.421% of its total share capital [2]. - MGM China (02282) repurchased 1 million shares for 15.75 million, with a year-to-date total of 2.58 million shares, representing 0.680% of its total share capital [2]. - Haier Smart Home (06690) repurchased 600,000 shares for 15.17 million, with a year-to-date total of 1.65 million shares, accounting for 0.058% of its total share capital [2]. - Other companies such as Coolpad Group (02369) and Xinyi International (00732) also engaged in buybacks, with Coolpad repurchasing 1.088 million shares for 1.38 million, representing 7.166% of its total share capital [2].

Group 1 - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan [1] - The total amount allocated for the buyback is HKD 1.4027 million [1] - The company plans to repurchase 100,000 shares at a price range of HKD 13.99 to HKD 14.06 per share [1]

Group 1 - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback on September 25, 2025, spending HKD 1.4027 million to repurchase 100,000 shares [1] - The repurchase price per share ranged from HKD 13.99 to HKD 14.06 [1]

Group 1 - The company, He Bo Pharmaceutical-B (02142.HK), announced a share buyback on September 25, 2023, spending HKD 1.403 million to repurchase 100,000 shares [1]

公司名稱： 和鉑醫藥控股有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年9月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | 每股發行/出售價 (註4) | | | | 已發行股份（不包括庫存股份 ...

Core Viewpoint - The report from Xingzheng International forecasts significant growth for Heptares Therapeutics (02142), with projected net profits of $0.81 billion, $0.43 billion, and $0.60 billion for 2025-2027, reflecting year-on-year growth rates of 2804.4%, -46.6%, and 39.7% respectively, and assigns an "Overweight" rating based on a PE ratio of 22.8, 42.6, and 30.5 times for the respective years [1] Group 1 - The company's revenue for the first half of 2025 is expected to reach $1.01 billion, representing a 327% increase, with a net profit of $0.73 billion, up 5125% [2] - Licensing revenue surged from $20.83 million to $93.71 million, marking a 350% increase [2] - A strategic global collaboration agreement with AstraZeneca includes potential upfront payments and milestone payments totaling $1.75 billion, with additional development and commercial milestone payments potentially reaching $4.4 billion [2] Group 2 - HBM7020, developed using proprietary technology, is being repositioned for autoimmune diseases, with IND preparations underway [3] - A licensing agreement with Otsuka Pharmaceutical for HBM7020 includes an upfront payment of $47 million and milestone payments [3] Group 3 - HBM4003, a next-generation fully human anti-CTLA-4 antibody, is set to present Phase II clinical data at the 2025 ESMO conference [4] - The company has a diverse pipeline in the next-generation I/O field, including PD-L1xCD40 and PD-1xVEGF candidates [4] Group 4 - HBM9378, the second fully human TSLP monoclonal antibody globally, is expected to initiate Phase II trials for asthma/COPD in China in the second half of 2025 [5] - The collaboration with WindwardBio for the POLARIS Phase II clinical study in asthma is anticipated to yield data by mid-2026 [5]